دورية أكاديمية
أعرض في EDS

Reconsider radiation exposure from imaging during immune checkpoint inhibitor trials to reduce risk of secondary cancers in long-term survivors?

التفاصيل البيبلوغرافية
العنوان: Reconsider radiation exposure from imaging during immune checkpoint inhibitor trials to reduce risk of secondary cancers in long-term survivors?
المؤلفون: Knapen DG; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands., de Groot DJA; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands., Kwee TC; Department of Radiology, Medical Imaging Center, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands., Meijne EIM; Department of Patient Care, Quality and Safety, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands., Fehrmann RSN; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands., de Vries EGE; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. Electronic address: e.g.e.de.vries@umcg.nl.
المصدر: Cancer treatment reviews [Cancer Treat Rev] 2020 Jul; Vol. 87, pp. 102027. Date of Electronic Publication: 2020 May 04.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 7502030 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1967 (Electronic) Linking ISSN: 03057372 NLM ISO Abbreviation: Cancer Treat Rev Subsets: MEDLINE
أسماء مطبوعة: Publication: 2003- : Amsterdam : Elsevier
Original Publication: London, New York, Academic Press.
مواضيع طبية MeSH: Cancer Survivors/*statistics & numerical data , Neoplasms/*diagnostic imaging , Neoplasms, Radiation-Induced/*epidemiology, Adult ; Female ; Humans ; Magnetic Resonance Imaging/statistics & numerical data ; Male ; Neoplasms/drug therapy ; Neoplasms/epidemiology ; Neoplasms/immunology ; Neoplasms, Radiation-Induced/etiology ; Tomography, X-Ray Computed/statistics & numerical data ; Young Adult
مستخلص: Immune checkpoint inhibitors (ICI) have improved outcomes for patients with advanced cancers, and results in increasing numbers of long-term survivors. For registration studies, progression-free survival and disease-free survival often serve as primary endpoints. This requires repeated computed tomography (CT) scans for tumour imaging which might lead to major radiation exposure. To determine this, all immune checkpoint inhibitors trials that led to FDA approval were retrieved up to July 29, 2019. From the available protocols, imaging modalities and schedules used in each trial were identified. The anticipated cumulative number of scans made after 1, 3, 5, and 10 years study participation were calculated. The percentage of lifetime attributable cancer risk was calculated using the Biological Effects of Ionizing Radiation VII report. Fifty-one trials were identified, from which 39 protocols were retrieved. Four were adjuvant trials. All protocols required repeated chest-abdomen imaging and specified CT scans as preferred imaging modality. Median calculated cumulative numbers of chest-abdomen CT scans after 1, 3, 5, and 10 years study participation were 7, 16, 24 and 46, respectively. For ages 20-70 years at study entry, the average lifetime attributable cancer risk after 1 year of study participation ranged from 1.11 to 0.40% for men and from 1.87 to 0.46% for women. At 10 years study participation, this risk increased to a range of 5.91 to 1.96% for men and 9.64 to 2.32% for women. Given high imaging radiation exposure for long-term survivors in current ICI trials an adaptive imaging interval and imaging termination rules should be considered for long-term survivors.
Competing Interests: Declaration of Competing Interest De Vries reports Institutional Financial Support for her advisory role from Daiichi Sankyo, Merck, NSABP, Pfizer, Sanofi, Synthon and Institutional Financial Support for clinical trials or contracted research from Amgen, AstraZeneca, Bayer, Chugai Pharma, CytomX Therapeutics, G1 Therapeutics, Genentech, Nordic Nanovector, Radius Health, Regeneron, Roche, Synthon, all outside the submitted work. The other authors do not report any conflict of interest.
(Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.)
فهرسة مساهمة: Keywords: Checkpoint inhibitor trials; Computed tomography; Ionizing radiation; Lifetime attributable secondary cancer risk
تواريخ الأحداث: Date Created: 20200520 Date Completed: 20200624 Latest Revision: 20200624
رمز التحديث: 20240628
DOI: 10.1016/j.ctrv.2020.102027
PMID: 32428791
قاعدة البيانات: MEDLINE
الوصف
تدمد:1532-1967
DOI:10.1016/j.ctrv.2020.102027